Camrelizumab: First Global Approval

Drugs. 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0.

Abstract

Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Squamous Cell / drug therapy
  • China
  • Drug Approval
  • Esophageal Neoplasms / drug therapy
  • Hodgkin Disease / drug therapy*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lymphoma, B-Cell / drug therapy
  • Nasopharyngeal Neoplasms / drug therapy
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Stomach Neoplasms / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • camrelizumab